A kind of co-crystal-like drug compound of basic protein and its preparation method and application

A technology of co-crystals and complexes is applied in the field of preparation and application of co-crystal-like-basic protein drug complexes, which can solve the phenomenon of tumor cell multidrug resistance, chemotherapy failure, and inability to effectively reverse tumor multidrug resistance. and other problems, to achieve the effect of solving multidrug resistance, high drug loading and simple composition

Active Publication Date: 2022-06-07
CHINA PHARM UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, chemotherapy is still the main treatment for clinical tumors. However, repeated use of chemotherapy drugs will cause tumor cells to develop multidrug resistance and eventually lead to chemotherapy failure.
Nano-preparations of chemotherapeutic drugs (such as paclitaxel albumin nanoparticles, doxorubicin liposomes, etc.) are mostly nano-preparations of a single chemical drug, which cannot effectively reverse the multidrug resistance of tumors; co-crystals can simultaneously encapsulate Two or more chemotherapeutic drugs can improve the sensitivity of tumor cells to chemotherapeutic drugs through the synergistic effect of multiple chemotherapeutic drugs, so as to better kill tumor cells. obvious advantage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of co-crystal-like drug compound of basic protein and its preparation method and application
  • A kind of co-crystal-like drug compound of basic protein and its preparation method and application
  • A kind of co-crystal-like drug compound of basic protein and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0069] Example 1: Formulation optimization of paclitaxel-disulfiram co-crystals

[0070] preparation process such as figure 1 As shown, the formulation optimization process is as follows:

[0071] (1) Effects of organic reagents on particle size and potential of paclitaxel-disulfiram co-crystals

[0072] Accurately weigh three groups of 5 mg of paclitaxel and 1 mg of disulfiram API and place them in EP tubes, respectively add 0.5 ml of ethanol / acetone / DMSO for ultrasonic dissolution as the organic phase; take 10 ml of dHSA solution as the aqueous phase and place them in a vial. , placed in an ice bath on ice for 5 minutes; under stirring (1500 r / min), the organic phase was added dropwise to the aqueous phase, continued stirring for 30 seconds, transferred to the probe for ultrasound, and 230W power ultrasound for 15 minutes under ice bath conditions , and the residual organic solvent was removed by evaporation under reduced pressure to obtain paclitaxel-disulfiram hybrid nan...

example 2

[0080] Example 2: Preparation of paclitaxel-disulfiram co-crystals

[0081] dHSA (1mg / ml) 10ml

[0082] Paclitaxel 10mg

[0083] Disulfiram 2mg

[0084] Ethanol 0.5ml

[0085] The preparation process is as follows:

[0086] Accurately weigh 10 mg of paclitaxel and 2 mg of disulfiram in a centrifuge tube, add 0.5 ml of ethanol for ultrasonic dissolution and use as the organic phase; take 10 ml of 1 mg / ml dHSA solution as the aqueous phase and place it in a vial, and place it on ice to pre-cool. 5 minutes; under stirring (1500 r / min), the organic phase was added dropwise to the aqueous phase, and after continuing to stir for 30 seconds, it was transferred to the probe for ultrasound, and 230W power was ultrasound for 15 minutes under ice bath conditions. Ethanol was removed to obtain paclitaxel-disulfiram co-crystals.

[0087] The obtained paclitaxel-disulfiram co-crystals were measured for particle size and potential, and the particle size results are shown in Figure 5 ,...

example 3

[0089] Example 3: Determination of Encapsulation Efficiency and Drug Loading Capacity of Paclitaxel-Disulfiram Co-crystals

[0090] In order to investigate the drug loading and encapsulation efficiency of the eutectic, the free drug in the preparation was separated by ultrafiltration and centrifugation, and the content of the drug in the nanoparticles was determined by high performance liquid chromatography. The specific steps are as follows: Precisely measure 1.5 ml of the eutectic-like crystal in Example 2 into an ultrafiltration tube, add 1.5 ml of equal volume of purified water and mix, centrifuge at 3500 rpm for 30 min, and take 20 μL of ultrafiltrate for injection , using high performance liquid chromatography to determine the content of free PTX and DSF, namely Wfree; take another 1ml of the same batch of eutectic, add 5ml methanol to break the demulsification, sonicate for 20min, after cooling to room temperature, add methanol to the mark, After filtration through a 0....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention belongs to the field of pharmaceutical preparations, in particular to the preparation and application of a co-crystal-like basic protein drug complex. The quasi-co-crystal is prepared by wrapping the chemotherapeutic drugs paclitaxel and disulfiram in denatured human serum albumin. Under physiological conditions, the co-crystal is negatively charged and can form a complex with basic protein through electrostatic interaction to increase the concentration of basic protein. stability and cell entry efficiency, so it is a good carrier system for basic protein delivery. The prepared co-crystal-like basic protein drug complex can deliver two small molecule drugs and one basic protein drug into the cell at the same time, achieving the effect of "killing three birds with one stone", so as to better kill drug resistance tumor cells. Compared with the existing protein delivery system, the present invention does not contain highly toxic polymers and solvents that are likely to cause allergic reactions, and is negatively charged under physiological conditions, so the biological safety is relatively high.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, in particular to the preparation and application of a quasi-co-crystal-basic protein pharmaceutical compound. Background technique [0002] Protein-based biomacromolecules have unique advantages in the field of tumor treatment, but due to their large molecular weight, instability and other factors, it is difficult to enter cells to play a role. Protein drugs include acidic proteins and basic proteins, where basic proteins are proteins with an isoelectric point (pI) above 7.5 and a net positive charge on the surface under physiological conditions, and acidic proteins are those with an isoelectric point (pI) below 7.5 and Proteins with a net negative charge on the surface under physiological conditions; the reported protein delivery carriers are mostly cationic polymers and cationic liposomes, etc. These carriers are only suitable for the delivery of acidic proteins, while the delivery sy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K47/62A61K47/69A61K31/337A61K31/145A61K38/41A61K38/38A61P35/00
CPCA61K47/62A61K47/6931A61K31/337A61K31/145A61K38/415A61K38/385A61P35/00A61K2300/00
Inventor 何伟邢续扬王孝春
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap